What question did this study set out to answer?

The aim is to evaluate sequencing quality metrics from FFPE tumor samples used in genomic profiling.

April 5, 2026

Abstract 5356: Leveraging a real-world clinicogenomic database for post-sequencing quality assessment in solid tumor comprehensive genomic profiling (CGP).

Puntos clave

The aim is to evaluate sequencing quality metrics from FFPE tumor samples used in genomic profiling.
Analyzed post-sequencing metrics from clinical tests over a 12-month period.
Utilized the OmniSeq INSIGHT test for comprehensive genomic profiling.
Involved 8,645 solid tumor samples from 19 distinct cancer types.
Evaluated key metrics assessing sequencing coverage and on-target mapping.
High-quality sequencing metrics were consistently achieved for both DNA and RNA across all tumor types.
The analysis reaffirmed the robustness of the workflows applied to various solid tumors.
Findings support the scalability and reliability of genomic profiling using FFPE tissue.

Resumen

Abstract The quantity and integrity of DNA and RNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor specimens can vary significantly due to factors such as block age, fixation conditions, protein crosslinking, and the presence of chemical inhibitors. Over a decade of research has demonstrated that, with optimized pre- and post-analytical workflows, FFPE samples can serve as reliable input material for both clinical and research-based next-generation sequencing (NGS) applications. Certain tumor types present additional challenges for nucleic acid extraction due to their biological characteristics, such as high metabolic activity and elevated nuclease levels. To evaluate sequencing quality across diverse tumor tissue types, we analyzed post-sequencing metrics from clinical tests performed over a 12-month period using the OmniSeq INSIGHT test for CGP. The cohort included 8,645 solid tumor samples representing 19 distinct cancer types. The most frequently profiled tumors were lung (N=3,984), colorectal (N=1,211), breast (N=578), pancreatic (N=398), prostate (N=331), uterine (N=252), esophageal (N=232), and head and neck (N=221). Key post-sequencing quality metrics that assess sequencing coverage and on target mapping were evaluated. Across all indications, high-quality data metrics were consistently achieved for both DNA and RNA, underscoring the robustness of the workflow regardless of tumor type. These findings support the scalability and reliability of CGP using FFPE tissue across a broad spectrum of solid tumors, reinforcing its utility in clinical oncology and research applications for high-quality genomic reporting. Citation Format: Erin N. Newburn, Rebecca A. Previs, Michelle F. Green, Kyle C. Strickland, Heidi Ko, Taylor Jensen, Eric Severson, Hardik Parikh, Maria-Fernanda Senosain, Jie An, Erik Van Roey, Daniel Metzger, R.J. Seager, Mark Sausen, Jennifer Jackson, Kenneth Valkenburg, Brian Caveney, Marcia Eisenberg, Shakti Ramkissoon. Leveraging a real-world clinicogenomic database for post-sequencing quality assessment in solid tumor comprehensive genomic profiling (CGP) abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5356.

Me gusta

Guardar